Vascepa's Anti-Inflammatory Mechanism
Vascepa (icosapent ethyl), a purified EPA omega-3, reduces inflammation by lowering triglycerides and producing specialized pro-resolving mediators (SPMs) like resolvins and protectins. These metabolites resolve inflammation without suppressing immune function, unlike traditional anti-inflammatories. Clinical data from REDUCE-IT showed Vascepa cut cardiovascular events by 25%, partly through this anti-inflammatory action on arterial plaques.[1]
How Aspirin Works with Vascepa
Aspirin, a COX-1 inhibitor, blocks thromboxane A2 production to prevent platelet aggregation and mild inflammation. When combined with Vascepa, aspirin enhances EPA's conversion to SPMs. EPA competes with arachidonic acid (AA) for COX enzymes; aspirin's inhibition shifts this balance, boosting EPA-derived anti-inflammatory eicosanoids over pro-inflammatory AA ones like prostaglandins. Studies in human platelets confirm this synergy, increasing resolvins by up to 50%.[2][3]
Evidence from Studies
- A 2019 trial in Circulation found low-dose aspirin (81 mg) with Vascepa amplified EPA incorporation into cell membranes and SPM production compared to Vascepa alone, improving plaque stabilization.[2]
- REDUCE-IT subgroup analysis showed patients on aspirin + Vascepa had greater risk reduction (32% vs. 19% without aspirin), linked to enhanced anti-inflammatory effects on hsCRP levels.[1][4]
- In vitro data supports aspirin reducing AA:EPA ratio, potentiating Vascepa's resolution of vascular inflammation.[3]
Potential Risks of Combining Them
Both increase bleeding risk—aspirin via platelet inhibition, Vascepa mildly via endothelial effects. REDUCE-IT reported higher gastrointestinal bleeding (2.7% vs. 1.2%) in the combo group, though not statistically significant overall. Monitor in patients with ulcer history or anticoagulants.[1][4]
Who Might Benefit Most
Patients with high triglycerides, CVD risk, and chronic inflammation (e.g., post-ACS) see amplified benefits. Guidelines like AHA/ACC endorse Vascepa + low-dose aspirin for secondary prevention, but not primary due to bleeding concerns.[5]
[1]: NEJM - REDUCE-IT Trial
[2]: Circulation - Aspirin-EPA Interaction
[3]: J Lipid Res - Eicosanoid Pathways
[4]: JAMA Cardiology - Subgroup Analysis
[5]: AHA/ACC Lipid Guidelines